Skip to search formSkip to main contentSkip to account menu

Antegren

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Natalizumab (Tysabri®, formerly known as Antegren®, Elan Pharmaceuticals [Elan; San Francisco, CA, USA] and Biogen Idec [Biogen… 
Highly Cited
2004
Highly Cited
2004
Natalizumab (Antegren™, Elan Corp. plc.; Biogen Idec.) is the first α4-integrin antagonist in the class of selective adhesion… 
2004
2004
In this open-label drug-interaction trial, we studied 38 patients with relapsing-remitting multiple sclerosis (MS) who received 3… 
Review
2004
Review
2004
Natalizumab (Antegren, Elan Corp. plc.; Biogen Idec.) is the first alpha4-integrin antagonist in the class of selective adhesion… 
Review
2004
Review
2004
  • Drugs in R&D
  • 2004
  • Corpus ID: 6136105
Natalizumab [AN 100226, anti-alpha4 integrin monoclonal antibody, Antegren] is a humanised monoclonal antibody that blocks… 
2002
2002
ZusammenfassungAntegren (Natalizumab) ist ein “humanisierter” monoklonaler Antikörper, der an die α4-Untereinheit von α4β1… 
2002
2002
Antegren (Natalizumab) is a humanized monoclonal antibody directed against alpha 4-integrin. This antibody binds to the alpha 4… 
Highly Cited
1999
Highly Cited
1999
OBJECTIVE To determine the effect of humanized monoclonal antibody against alpha4 integrin (reactive with alpha4beta1 integrin or… 
Highly Cited
1999
Highly Cited
1999
Objective: To determine the effect of humanized monoclonal antibody against α4 integrin (reactive with α4β1 integrin or very-late… 
1998
1998
  • M. Elices
  • IDrugs : the investigational drugs journal
  • 1998
  • Corpus ID: 37916434
AN-100226 (Antegren), a humanized monoclonal antibody (MAb) directed against the alpha4beta1 integrin (VLA-4) expressed on…